Navigation Links
Telik Announces Presentation and Webcast at Needham Biotechnology Conference
Date:6/5/2008

PALO ALTO, Calif., June 5 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference in New York City on Wednesday, June 11, 2008 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, http://www.telik.com.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces First Quarter 2008 Financial Results
2. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
3. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
4. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
7. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
8. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
9. Biopure Announces MHRA Meeting Update
10. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
11. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):